We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Read MoreHide Full Article
Key Takeaways
Eli Lilly's Reta boosts optimism for next-gen obesity drugs and long-term GLP-1 growth.
GLP-1 drugs are expanding beyond obesity into heart, kidney, liver and addiction care.
ETFs like OZEM, HRTS and THNR offer diversified exposure to the weight-loss boom.
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035, per WHO and Goldman Sachs. The global market for anti-obesity medications is expected to reach $50 billion by 2030.
As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.
Eli Lilly Hovers Around $1 Trillion Valuation
Eli Lilly (LLY - Free Report) shares hit a $1 trillion market value, closing at its first record high since November. The stock has surged more than 25% since the March 30 market low and gained over 400% in the past five years, making Eli Lilly one of Wall Street’s biggest beneficiaries of the obesity-drug boom, per Yahoo Finance. Shares surged about 14% over the past one month (as of June 4, 2026).
Reta Fuels Investor Optimism
Much of the recent excitement centers on retatrutide, or “Reta,” Eli Lilly’s experimental next-generation obesity treatment.
Unlike approved drugs such as Zepbound and Mounjaro, which target two hormone pathways, Reta targets three pathways tied to appetite control, blood sugar regulation and energy use.
In the Phase 3 TRIUMPH-1 obesity trial, patients on the highest dose lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks. More than 45% of participants lost at least 30% of their body weight, results often associated with bariatric surgery, per the same Yahoo Finance article.
GLP-1 Market Expands Beyond Obesity
Investors increasingly view GLP-1 drugs as a broader metabolic-health platform extending beyond obesity and diabetes into areas such as sleep apnea, kidney disease, cardiovascular risk, liver disease and addiction treatment.
The trend is also affecting industries outside healthcare, including packaged food, alcohol, restaurant and retail stocks, as investors assess how appetite-suppressing drugs may reshape consumer behavior.
Deloitte Warns of a GLP-1 “Bubble”
A new report from Deloitte suggests soaring demand for obesity and diabetes drugs may be creating a “bubble effect” within the pharmaceutical industry, as quoted on CNBC.
Returns on pharmaceutical R&D among the world’s top 20 drugmakers rose to 7% in 2025, driven largely by GLP-1-related assets. Obesity treatments now account for roughly 25% of projected late-stage pipeline sales, surpassing oncology for the first time in 16 years.
According to Deloitte, GLP-1 and obesity drugs now represent about 38% of projected commercial inflows from the 2025 late-stage pipeline. Excluding these drugs, the industry’s R&D return falls sharply to 2.9%.
The report also highlighted concentration risk, noting that only 9% of blockbuster late-stage therapies is expected to generate nearly 70% of total risk-adjusted peak sales.
AI and Health Tech Join the GLP-1 Boom
The obesity-drug trend is also driving growth in health technology. Health-tech startup Signos recently raised $20 million in funding and expanded its partnership with Dexcom, per a CNBC article.
Signos uses AI-powered glucose monitoring technology alongside Dexcom’s continuous glucose monitors to help users manage weight through personalized recommendations tied to food, sleep, stress and lifestyle habits.
ETFs to Play
Roundhill GLP-1 and Weight Loss ETFOZEM, Tema Heart & Health ETF (HRTS - Free Report) and Amplify Weight Loss Drug & Treatment ETF (THNR - Free Report) are some of the ETFs that should be closely tracked in light of the above-mentioned scenario.
LLY-heavy ETFs like the iShares U.S. Pharmaceuticals ETF (IHE - Free Report) , Harbor Health Care ETF (MEDI - Free Report) and VanEck Pharmaceutical ETF (PPH - Free Report) should also benefit from this trend.
NVO-heavy ETFs such as the Simplify Health Care ETF (PINK - Free Report) and PPH are also in focus. Meanwhile, Amgen-heavy ETFs like the VanEck Biotech ETF (BBH - Free Report) and iShares Biotechnology ETF (IBB - Free Report) should not be overlooked amid this euphoria.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Key Takeaways
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035, per WHO and Goldman Sachs. The global market for anti-obesity medications is expected to reach $50 billion by 2030.
As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.
Eli Lilly Hovers Around $1 Trillion Valuation
Eli Lilly (LLY - Free Report) shares hit a $1 trillion market value, closing at its first record high since November. The stock has surged more than 25% since the March 30 market low and gained over 400% in the past five years, making Eli Lilly one of Wall Street’s biggest beneficiaries of the obesity-drug boom, per Yahoo Finance. Shares surged about 14% over the past one month (as of June 4, 2026).
Reta Fuels Investor Optimism
Much of the recent excitement centers on retatrutide, or “Reta,” Eli Lilly’s experimental next-generation obesity treatment.
Unlike approved drugs such as Zepbound and Mounjaro, which target two hormone pathways, Reta targets three pathways tied to appetite control, blood sugar regulation and energy use.
In the Phase 3 TRIUMPH-1 obesity trial, patients on the highest dose lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks. More than 45% of participants lost at least 30% of their body weight, results often associated with bariatric surgery, per the same Yahoo Finance article.
GLP-1 Market Expands Beyond Obesity
Investors increasingly view GLP-1 drugs as a broader metabolic-health platform extending beyond obesity and diabetes into areas such as sleep apnea, kidney disease, cardiovascular risk, liver disease and addiction treatment.
Alongside Eli Lilly, Novo Nordisk (NVO - Free Report) , Amgen (AMGN - Free Report) and Viking Therapeutics (VKTX - Free Report) remain key players in the obesity-drug race. Meanwhile, Indian pharma major Lupin bets big on India’s GLP-1 market.
The trend is also affecting industries outside healthcare, including packaged food, alcohol, restaurant and retail stocks, as investors assess how appetite-suppressing drugs may reshape consumer behavior.
Deloitte Warns of a GLP-1 “Bubble”
A new report from Deloitte suggests soaring demand for obesity and diabetes drugs may be creating a “bubble effect” within the pharmaceutical industry, as quoted on CNBC.
Returns on pharmaceutical R&D among the world’s top 20 drugmakers rose to 7% in 2025, driven largely by GLP-1-related assets. Obesity treatments now account for roughly 25% of projected late-stage pipeline sales, surpassing oncology for the first time in 16 years.
According to Deloitte, GLP-1 and obesity drugs now represent about 38% of projected commercial inflows from the 2025 late-stage pipeline. Excluding these drugs, the industry’s R&D return falls sharply to 2.9%.
The report also highlighted concentration risk, noting that only 9% of blockbuster late-stage therapies is expected to generate nearly 70% of total risk-adjusted peak sales.
AI and Health Tech Join the GLP-1 Boom
The obesity-drug trend is also driving growth in health technology. Health-tech startup Signos recently raised $20 million in funding and expanded its partnership with Dexcom, per a CNBC article.
Signos uses AI-powered glucose monitoring technology alongside Dexcom’s continuous glucose monitors to help users manage weight through personalized recommendations tied to food, sleep, stress and lifestyle habits.
ETFs to Play
Roundhill GLP-1 and Weight Loss ETF OZEM, Tema Heart & Health ETF (HRTS - Free Report) and Amplify Weight Loss Drug & Treatment ETF (THNR - Free Report) are some of the ETFs that should be closely tracked in light of the above-mentioned scenario.
LLY-heavy ETFs like the iShares U.S. Pharmaceuticals ETF (IHE - Free Report) , Harbor Health Care ETF (MEDI - Free Report) and VanEck Pharmaceutical ETF (PPH - Free Report) should also benefit from this trend.
NVO-heavy ETFs such as the Simplify Health Care ETF (PINK - Free Report) and PPH are also in focus. Meanwhile, Amgen-heavy ETFs like the VanEck Biotech ETF (BBH - Free Report) and iShares Biotechnology ETF (IBB - Free Report) should not be overlooked amid this euphoria.